Lansoprazole as First‑Line Acid Suppression for Children with GERD

FDA Approval & Dosing

• Lansoprazole is FDA‑approved for children ≥ 1 year (up to 17 years) with dosing of 0.7–3.0 mg/kg/day; formulations include sprinkle capsules and flavored disintegrating tablets that can be mixed with soft foods or juice. 1
• For a toddler (≈ 2 years), initiate therapy with 0.7–1.0 mg/kg once daily taken before meals; treatment courses are recommended for a maximum of 12 weeks for symptomatic GERD or erosive esophagitis. 1

Efficacy Compared with H₂‑Receptor Antagonists

• In pediatric patients (1–12 years), lansoprazole at the above dosing improves GERD symptoms and achieves complete healing of erosive esophagitis, outperforming H₂‑receptor antagonists in both symptom relief and endoscopic healing rates. 1
• Proton‑pump inhibitors (including lansoprazole) are consistently more effective than H₂‑receptor antagonists for controlling reflux symptoms and promoting mucosal healing. [1][2]

Safety Profile & Adverse Effects

• Short‑term use is generally well tolerated, but long‑term therapy is associated with an increased risk of lower respiratory tract infections in infants and young children. [1][2]
• Common adverse events (headache, diarrhea, constipation, nausea) occur in up to 14 % of pediatric patients receiving lansoprazole. 1
• Histologic changes (enterochromaffin cell hyperplasia) have been observed in up to 50 % of children on PPIs for >2.5 years, indicating a need for periodic reassessment of therapy duration. [1][2]

Limitations of H₂‑Receptor Antagonists (e.g., Ranitidine)

• Rapid tachyphylaxis develops within ~6 weeks of H₂‑receptor antagonist initiation, markedly reducing long‑term efficacy. [1][2]
• H₂‑receptor antagonists are less effective than PPIs for both symptom control and endoscopic healing of erosive esophagitis. [1][2]

Indications, Contraindications & Clinical Decision‑Making

• Acid suppression should be confirmed as necessary; placebo‑controlled trials show PPIs do not outperform placebo for reducing irritability in infants with uncomplicated reflux, underscoring the importance of appropriate indication. [1][2]
• Red‑flag features that mandate further diagnostic evaluation (e.g., projectile or bile‑stained vomiting, hematemesis, bloody stools, abdominal distension, systemic illness) should be sought before initiating pharmacotherapy. 3
• For uncomplicated regurgitation, first‑line management consists of lifestyle modifications—feeding thickening, positional changes, and parental reassurance—prior to any medication. 3

Practical Administration & Monitoring

• Open the capsule and sprinkle its contents onto a small amount of soft food (e.g., applesauce, yogurt) or mix with juice; administer before meals for optimal acid suppression. Do not crush or chew the granules. 1
• Reassess the need for continued therapy at regular intervals (e.g., every 4–6 weeks); discontinue or step‑down treatment once symptoms are controlled, as long‑term use beyond 12 months lacks supporting evidence. 1

All statements are derived from peer‑reviewed pediatric literature (Pediatrics 2013; BMJ 2015) and reflect the current evidence base for lansoprazole use in children with gastroesophageal reflux disease.